公开(公告)号：EP2913673A1

公开(公告)日：2015-09-02

申请号：EP14179937.9

申请日：2002-08-29

Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTE

Inventor： Schummer, Michel ,  Hellstrom, Ingegerd ,  Hellstrom, Karl, Erik ,  Ledbetter, Jeffrey, A ,  Hayden-Ledbetter, Martha

IPC: G01N33/574 ,  C07K14/81 ,  C07K16/30 ,  C07K16/40 ,  C07K16/18 ,  A61K39/00

CPC classification number: G01N33/57449 ,  A61K2039/505 ,  C07K14/811 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3069 ,  C07K16/40 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/57488 ,  G01N2333/705

Abstract: Provided are methods of screening for the presence of ovarian carcinoma in a subject. The methods involved contacting a blood, serum, or plasma sample from the subject with an antibody specific for the polypeptide of SEQ ID NO:11. This allows determination of the presence in the biological sample of a molecule that naturally occurs in soluble form, and has an antigenic determinant that is reactive with the antibody. This, in turn, allows detection of the presence of a malignant condition in the subject. The antibody may be a monoclonal antibody, such as a murine monoclonal antibody. Detection of the binding of the antibody to the antigenic determinant may be effected via spectrophotometric detection of a product of an enzyme reaction, for example via enzyme linked immunosorbent assay (ELISA). The subject may have an early stage of ovarian cancer.

Abstract translation: 提供筛选受试者卵巢癌存在的方法。 所述方法包括使来自受试者的血液，血清或血浆样品与对SEQ ID NO：11的多肽具有特异性的抗体接触。 这允许确定天然以可溶形式发生的分子的生物样品中的存在，并且具有与抗体反应的抗原决定簇。 这反过来又允许检测受试者中是否存在恶性病症。 抗体可以是单克隆抗体，例如鼠单克隆抗体。 抗体与抗原决定簇的结合的检测可以通过酶反应的产物的分光光度法检测，例如通过酶联免疫吸附测定（ELISA）进行。 受试者可能有卵巢癌的早期阶段。

公开(公告)号：EP2913673B1

公开(公告)日：2017-05-31

申请号：EP14179937.9

申请日：2002-08-29

Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTE

Inventor： Schummer, Michel ,  Hellstrom, Ingegerd ,  Hellstrom, Karl, Erik ,  Ledbetter, Jeffrey, A ,  Hayden-Ledbetter, Martha

IPC: G01N33/574 ,  C07K14/81 ,  C07K16/30 ,  C07K16/40 ,  C07K16/18 ,  A61K39/00

CPC classification number: G01N33/57449 ,  A61K2039/505 ,  C07K14/811 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3069 ,  C07K16/40 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/57488 ,  G01N2333/705

公开(公告)号：EP2322933A1

公开(公告)日：2011-05-18

申请号：EP10184645.9

申请日：2002-08-29

Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTE

Inventor： Schummer, Michel ,  Hellstrom, Ingegerd ,  Hellstrom, Karl, Erik ,  Ledbetter, Jeffrey, A. ,  Hayden-Ledbetter, Martha

IPC: G01N33/574 ,  C07K16/30 ,  C12N15/62 ,  C12N15/11 ,  C12N15/85 ,  C12N5/10 ,  C12Q1/68

CPC classification number: G01N33/57449 ,  A61K2039/505 ,  C07K14/811 ,  C07K16/18 ,  C07K16/30 ,  C07K16/3069 ,  C07K16/40 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/57488 ,  G01N2333/705

Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.

Abstract translation: 本发明涉及用于检测恶性病症的组合物和方法，涉及HE4a多肽的可溶性和细胞表面形式的发现，包括在卵巢癌中过表达的HE4a。 特别地，本发明提供了编码HE4a的核酸序列，并且还提供了通过检测对具有天然存在于可溶性和/或可溶性的分子的HE4a多肽的特异性抗体的反应性来筛选受试者中恶性病症的存在的方法 来自这样的受试者的样品中的细胞表面形式，以及使用HE4a核苷酸序列的杂交筛选以及其它相关优点。